You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

DURANEST Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Duranest patents expire, and what generic alternatives are available?

Duranest is a drug marketed by Astrazeneca and Dentsply Pharm and is included in two NDAs.

The generic ingredient in DURANEST is etidocaine hydrochloride. Additional details are available on the etidocaine hydrochloride profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DURANEST?
  • What are the global sales for DURANEST?
  • What is Average Wholesale Price for DURANEST?
Summary for DURANEST
US Patents:0
Applicants:2
NDAs:2
Raw Ingredient (Bulk) Api Vendors: 33
Patent Applications: 4,326
DailyMed Link:DURANEST at DailyMed
Drug patent expirations by year for DURANEST

US Patents and Regulatory Information for DURANEST

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca DURANEST epinephrine; etidocaine hydrochloride INJECTABLE;INJECTION 017751-004 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Astrazeneca DURANEST etidocaine hydrochloride INJECTABLE;INJECTION 017751-003 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Astrazeneca DURANEST epinephrine bitartrate; etidocaine hydrochloride INJECTABLE;INJECTION 017751-006 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Astrazeneca DURANEST epinephrine bitartrate; etidocaine hydrochloride INJECTABLE;INJECTION 017751-007 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Dentsply Pharm DURANEST epinephrine bitartrate; etidocaine hydrochloride INJECTABLE;INJECTION 021384-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DURANEST

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca DURANEST etidocaine hydrochloride INJECTABLE;INJECTION 017751-005 Approved Prior to Jan 1, 1982 ⤷  Subscribe ⤷  Subscribe
Astrazeneca DURANEST etidocaine hydrochloride INJECTABLE;INJECTION 017751-005 Approved Prior to Jan 1, 1982 ⤷  Subscribe ⤷  Subscribe
Astrazeneca DURANEST epinephrine bitartrate; etidocaine hydrochloride INJECTABLE;INJECTION 017751-007 Approved Prior to Jan 1, 1982 ⤷  Subscribe ⤷  Subscribe
Astrazeneca DURANEST etidocaine hydrochloride INJECTABLE;INJECTION 017751-005 Approved Prior to Jan 1, 1982 ⤷  Subscribe ⤷  Subscribe
Astrazeneca DURANEST epinephrine; etidocaine hydrochloride INJECTABLE;INJECTION 017751-004 Approved Prior to Jan 1, 1982 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for DURANEST

See the table below for patents covering DURANEST around the world.

Country Patent Number Title Estimated Expiration
Denmark 139814 ⤷  Subscribe
Australia 468489 ⤷  Subscribe
Italy 1066334 COMPOSIZIONE AN ESTETICA LOCALE DELLA 2-ALCHIL-2-ALCHIL AMMINO 2',6' ACETOSSILIDIDE E RELATIVO PROCEDIMENTO DI PRODUZIONE ⤷  Subscribe
Finland 55027 ⤷  Subscribe
Netherlands 8204126 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.